Profile data is unavailable for this security.
About the company
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
- Revenue in TWD (TTM)4.90bn
- Net income in TWD240.77m
- Incorporated1995
- Employees480.00
- LocationFormosa Laboratories IncNo.36, Hoping Street, Kengkou VillageTAOYUAN 338TaiwanTWN
- Phone+886 33240895
- Fax+886 33240945
- Websitehttps://www.formosalab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formosa Pharmaceuticals Inc | 12.16m | -74.25m | 4.10bn | -- | -- | 2.71 | -- | 336.98 | -0.5083 | -0.5083 | 0.0818 | 10.00 | 0.0057 | -- | 4.64 | -- | -3.49 | -30.53 | -3.80 | -33.88 | 4.52 | -- | -610.20 | -758.21 | 9.55 | -- | 0.0161 | -- | 359.89 | 163.52 | 37.56 | -- | 103.21 | -- |
| Cenra Inc | 8.68bn | 293.68m | 5.08bn | 1.40k | 12.30 | 0.6663 | 7.97 | 0.5847 | 2.76 | 2.76 | 78.36 | 50.88 | 0.6976 | 1.98 | 5.75 | -- | 2.37 | 3.49 | 3.58 | 4.70 | 38.96 | 36.76 | 3.39 | 5.22 | 0.7294 | 6.48 | 0.294 | 50.31 | 4.01 | 2.28 | -1.53 | -3.78 | -8.43 | 4.92 |
| Panion & BF Biotech Inc | 2.04bn | 174.37m | 5.28bn | 321.00 | 30.31 | 2.78 | 16.71 | 2.59 | 2.03 | 2.03 | 23.77 | 22.18 | 0.6511 | 1.72 | 9.45 | -- | 5.57 | 3.46 | 8.14 | 4.90 | 53.74 | 52.04 | 8.55 | 5.28 | 0.8363 | 15.90 | 0.2529 | 123.31 | 7.85 | 5.22 | 61.26 | -5.05 | 10.70 | 0.3601 |
| Sinphar Pharmaceutical Co Ltd | 3.35bn | 345.57m | 5.81bn | 984.00 | 16.84 | 1.76 | 9.87 | 1.74 | 1.81 | 1.81 | 17.57 | 17.39 | 0.5401 | 2.53 | 6.94 | -- | 5.40 | 1.39 | 7.00 | 1.91 | 42.51 | 37.59 | 10.00 | 3.11 | 1.56 | 13.85 | 0.3188 | 69.66 | 6.33 | 5.64 | -18.78 | 85.26 | 7.75 | 40.11 |
| SCI Pharmtech Inc | 1.39bn | 115.35m | 6.21bn | 241.00 | 54.04 | 1.16 | 17.00 | 4.47 | 0.9623 | 0.9623 | 11.61 | 44.94 | 0.1974 | 1.60 | 4.99 | -- | 1.64 | 5.96 | 1.89 | 7.05 | 24.91 | 35.30 | 8.30 | 21.64 | 0.3841 | 2.56 | 0.1506 | 25.24 | 26.54 | -8.34 | 81.42 | -1.31 | 35.86 | -18.67 |
| Formosa Laboratories Inc | 4.90bn | 240.77m | 6.82bn | 480.00 | 28.59 | 0.8948 | 9.23 | 1.39 | 1.98 | 1.98 | 40.63 | 63.36 | 0.3565 | 1.56 | 5.42 | -- | 1.47 | 2.65 | 2.01 | 3.60 | 41.84 | 38.16 | 4.12 | 8.39 | 1.23 | 1.59 | 0.2908 | 41.08 | 8.50 | 11.38 | 24.58 | 68.35 | -16.19 | -- |
| Adimmune Corp | 1.20bn | -508.60m | 7.75bn | 564.00 | -- | 1.61 | -- | 6.45 | -1.21 | -1.21 | 2.85 | 11.21 | 0.1413 | 1.43 | 2.11 | -- | -7.07 | 0.5893 | -8.86 | 0.6742 | 2.67 | 32.30 | -50.05 | 2.71 | 1.42 | -49.73 | 0.4028 | 31.00 | -12.78 | 3.68 | 62.06 | -- | -15.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.58m | 2.14% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 528.85k | 0.44% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 182.00k | 0.15% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 138.12k | 0.12% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 69.72k | 0.06% |
| Goldman Sachs Asset Management LPas of 30 Sep 2025 | 56.00k | 0.05% |
| DFA Australia Ltd.as of 31 Dec 2025 | 42.38k | 0.04% |
| CI Investments, Inc.as of 30 Jun 2025 | 2.32k | 0.00% |
